Purple Biotech Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 6, 2025
Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms
Read more at globenewswire.com0.5925
-0.02 (-3.77%)
Find more stocks in the Stock Screener
PPBT Latest News and Analysis
